Safety Profile

AOD-9604 Side Effects & Safety

AOD-9604 has a favorable safety profile in Phase II human trials. It does not significantly affect IGF-1 or glucose, differentiating it from full-length GH.

Educational content only. This page is compiled from published research for reference and is not medical advice, diagnosis, or treatment. Readers should verify claims against primary sources and consult a qualified healthcare provider before making any health decisions. Full disclaimer.

Side effects by severity

Common1 effect

Injection site reactions

Mild erythema or itching.

Uncommon1 effect

Headache

Reported in clinical trials.

Rare2 effects

Nausea

Uncommon.

Fatigue

Rarely reported.

Contraindications

Known hypersensitivity
Pregnancy
Active malignancy (theoretical)

Drug interactions

Limited clinical interaction data
Additive with other lipolytic agents theoretically possible

Special populations

Not FDA approved. Not recommended in pregnancy. Limited elderly data.

Safety summary

AOD-9604 has a clean safety profile in Phase II weight-loss trials. Unlike full-length GH, it does not induce insulin resistance or IGF-1 elevation.

Frequently asked

Does AOD-9604 cause insulin resistance?

No — one of its advantages over full-length GH is that it retains lipolytic activity without affecting glucose tolerance.